Jason Johnson, MD, MBA, DABR
Cards
About
Research
Publications
2025
A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children
McGovern S, Johnson J, Luo D, Nguyen K, McAleer M, Paulino A, Grosshans D, Baxter P, Zaky W, Thall P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: e13-e14. DOI: 10.1016/j.ijrobp.2024.11.049.Peer-Reviewed Original ResearchDose-volume constraintsSymptomatic brain necrosisRecurrent brain tumorsBrain tumorsBrain necrosisPrimary endpointDose constraintsProton therapyProspective studyRecurrent pediatric brain tumorsMedian overall survivalMedian prescription doseCourse of radiationResults Median ageTreated with radiationPediatric brain tumorsPrimary brain tumorProgression of diseaseBrain reirradiationDosimetric guidelinesDose escalationPrescription doseOverall survivalMedian intervalProspective trialsDynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma.
Amer A, Ansari S, Krayyem A, Kundu S, Khose S, Pokhylevych H, Calle S, Patel C, Yang Z, Liu H, Johnson J. Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma. Journal Of Computer Assisted Tomography 2025 PMID: 39876523, DOI: 10.1097/rct.0000000000001716.Peer-Reviewed Original ResearchHigh-grade gliomasBlood-brain barrierDCE-MRIPeak contrast enhancementQuantify BBB permeabilityTreatment-related changesFollow-up subjectsKtrans mapsTrue progressionTumor progressionClinical dataConventional MRIPseudoprogressionBBB permeabilityCombined pathologyKtransContrast enhancementT1 enhancementStandard processing methodologyStatistically significant resultsClinical data setsPathologyPatientsGliomaSSS techniqueRadiologist, trainee, and logistical factors impacting the timeliness of CTA head and neck reporting in stroke code activations.
Zaree O, Nguyen J, de Oliveira Santo I, Kertam A, Rahmani S, Johnson J, Tu L. Radiologist, trainee, and logistical factors impacting the timeliness of CTA head and neck reporting in stroke code activations. American Journal Of Neuroradiology 2025, ajnr.a8660. PMID: 39832953, DOI: 10.3174/ajnr.a8660.Peer-Reviewed Original ResearchStroke code activationAttending radiologistsTimeliness of reportingEmergency department settingRadiologist characteristicsCare settingsMultivariate regression modelImprove workflow efficiencyDepartment settingStroke codeModifiable factorsDescriptive statisticsSecondary analysisCoding activitiesReport factorsPatient ageObservational studyWorkflow efficiencyShift typeMedian TATMultivariate regressionInterquartile rangeRegression modelsCTA reportsLogistical factors
2024
The Impact of MRI-Based Advanced Neuroimaging on Neuro-Oncologists’ Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey
Samir A. Dagher, MD, Ho-Ling Liu, PhD, Burak Berksu Ozkara, MD, Susana Calle, MD, Diana Kaya, MD, Maria K. Gule, MD, Noah N. Chasen, MD, Dawid Schellingerhout, MD, Kim O. Learned, MD, Komal B. Shah, MD, Jason M. Johnson, MD, Jia Sun, PhD, Donald F. Schomer, MD, Vinodh A. Kumar, MD, Max Wintermark, MD, Nazanin K. Majd, MD, PhD, Joo Yeon Nam, MD, Melissa M. Chen, MD. The Impact of MRI-Based Advanced Neuroimaging on Neuro-Oncologists’ Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey. AJR 2024 Aug 14 [published online]. Accepted manuscript. doi:10.2214/AJR.24.31595Peer-Reviewed Original ResearchDifferential tractography and whole brain connectometry in primary motor area gliomas resection: A feasibility study.
Figueredo LF, Mejía-Cordovez JA, Gomez-Amarillo DA, Hakim F, Pimienta-Redondo HD, Almeida JP, Kehayov I, Angelova P, Apostolov G, Luzzi S, Baldoncini M, Johnson JM, Ordóñez-Rubiano EG. Differential tractography and whole brain connectometry in primary motor area gliomas resection: A feasibility study. Clin Neurol Neurosurg 2024, 241: 108305. PMID: 38713964, DOI: 10.1016/j.clineuro.2024.108305.Peer-Reviewed Original ResearchTucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.
O'Brien B, Murthy R, Berry D, Singareeka Raghavendra A, Gule-Monroe M, Johnson J, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Melisko M, Morikawa A, Ferguson S, de Groot J, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin N, Stringer-Reasor E. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. Journal Of Clinical Oncology 2024, 42: 2018-2018. DOI: 10.1200/jco.2024.42.16_suppl.2018.Peer-Reviewed Original ResearchHER2+ breast cancerLeptomeningeal metastasesPatient-reported outcomesBreast cancerObjective responseClinical examCSF cytologyEvidence of clinically meaningful benefitHER2-targeted tyrosine kinase inhibitorsMedian time to CNS progressionMetastatic HER2+ breast cancerKarnofsky performance status >Treatment of leptomeningeal metastasesAbnormal CSF cytologyPerformance status >Targeted neurological deficitsMDASI-BTPhase 2 studyTyrosine kinase inhibitorsClinically meaningful benefitPre-specified timepointsPreliminary efficacy dataCNS progressionMedian OSCNS metastasesAdditive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas
Yadav D, Upadhyay R, Kumar V, Chen M, Johnson J, Langshaw H, Curl B, Farhat M, Talpur W, Beckham T, Yeboa D, Swanson T, Ghia A, Li J, Chung C. Additive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas. Practical Radiation Oncology 2024, 14: e449-e457. PMID: 38685448, DOI: 10.1016/j.prro.2024.04.009.Peer-Reviewed Original ResearchPseudo-progressionResponse assessmentInterobserver agreementImprove response assessmentPost-operative MRIFollow-up MRIFollow-up imagingEvaluate treatment responseHigh-grade gliomasIndependent blinded reviewIdentification of patientsClinical trial enrollmentWeeks of RTPartial response(PRStable disease(SDRT planningSalvage treatmentTumor responseEarly time pointsMedian intervalImprove patient outcomesTrue progressionProspective studyTreatment responseTumor progressionExpert-centered Evaluation of Deep Learning Algorithms for Brain Tumor Segmentation.
Hoebel K, Bridge C, Ahmed S, Akintola O, Chung C, Huang R, Johnson J, Kim A, Ly K, Chang K, Patel J, Pinho M, Batchelor T, Rosen B, Gerstner E, Kalpathy-Cramer J. Expert-centered Evaluation of Deep Learning Algorithms for Brain Tumor Segmentation. Radiology Artificial Intelligence 2024, 6: e220231. PMID: 38197800, PMCID: PMC10831514, DOI: 10.1148/ryai.220231.Peer-Reviewed Original ResearchConceptsBrain tumor segmentationDeep learning algorithmsSegmentation qualityLearning algorithmsTumor segmentationBrain tumor segmentation algorithmQuantitative quality metricsTumor segmentation algorithmClinical expert evaluationSegmentation performanceAlgorithm evaluationSegmentation algorithmQuality metricsDice scoreHausdorff distanceSegmentation casesAlgorithmExperimental resultsExpert evaluationQuality evaluationMetricsSurvey article
2023
Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Nagarajan P, Maronge J, Johnson J, Rosenthal D, Myers J, Gross N. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology - Head & Neck Surgery 2023, 149: 847-849. PMID: 37535378, PMCID: PMC10401391, DOI: 10.1001/jamaoto.2023.1729.Peer-Reviewed Original ResearchAdvances in the Radiological Evaluation of and Theranostics for Glioblastoma
Hooper G, Ansari S, Johnson J, Ginat D. Advances in the Radiological Evaluation of and Theranostics for Glioblastoma. Cancers 2023, 15: 4162. PMID: 37627190, PMCID: PMC10453051, DOI: 10.3390/cancers15164162.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Academic Achievements & Community Involvement
Clinical Care
Overview
Jason Johnson, MD, is a neuroradiologist who specializes in imaging techniques to diagnose and evaluate conditions affecting the brain and nervous system, including brain tumors, stroke, and other neurological disorders.
He utilizes advanced imaging methods to provide detailed insights into these conditions, aiding in accurate diagnosis and effective treatment planning.
An associate professor of radiology and biomedical imaging at Yale School of Medicine, Dr. Johnson completed his medical training at the University of Arizona, followed by a residency in radiology at the University of Vermont and fellowship training in neuroradiology at both the University of California, San Francisco, and Massachusetts General Hospital/Harvard Medical School.
Dr. Johnson has been recognized with the Magna Cum Laude Merit Award by the International Society of Magnetic Resonance in Medicine.
Clinical Specialties
Neuroradiology
Get In Touch
Contacts
Appointment Number